Gilead Sciences Inc
NASDAQ: GILD
$88.40
-$3.71 (-4.0%)
Closing Price on November 15, 2024
GILD Articles
Needless to say, the past two years have been rough on biotech. The question for investors is which of the stocks hold the best potential in 2017.
Published:
Last Updated:
The December 15 short interest data have been compared with the previous report, and short interest was down in most of the selected biotech stocks.
Published:
Last Updated:
The November 30 short interest data have been compared with the previous report, and short interest was mixed in the selected biotech stocks.
Published:
Last Updated:
December 8, 2016: Here are four stocks trading with relatively heavy volume among 34 equities making new 52-week lows in Thursday’s session. On the NYSE, advancers led decliners by about 3 to 2 and...
Published:
Last Updated:
The November 15 short interest data have been compared with the previous report, and short interest increased in most of the selected biotech stocks.
Published:
Last Updated:
Gilead Sciences has announced that the FDA has approved its once-a-day treatment for adults with chronic hepatitis B virus infection.
Published:
Last Updated:
Now that the U.S. presidential election is over and Hillary Clinton is out of the picture, major biotech companies can breathe a little easier knowing that the pressure is off, if for just now at...
Published:
Last Updated:
If you just looked at formal Buy and Sell ratings from Wall Street analysts, you might assume that everything is still fine and hopeful for Gilead Sciences.
Published:
Last Updated:
Gilead Sciences Inc. (NASDAQ: GILD) released third-quarter earnings report after markets closed on Tuesday. Despite negative news coming out on Tuesday with former presidential candidate Bernie...
Published:
Last Updated:
Although Gilead has been falling for about a year now, the valuation is looking more favorable — assuming Gilead is not a value trap. The earnings report will help shed some light on where the...
Published:
Last Updated:
24/7 Wall St. has put together a preview of Pfizer, Starbucks and some of the major companies reporting their quarterly results this week.
Published:
Last Updated:
The October 14 short interest data have been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
Last Updated:
Americans generally would like to spend less money on health care. One way that this can be and will be accomplished is through the continued use and expanded use of generic drugs.
Published:
Last Updated:
These top biotech companies have been absolutely hammered and now trade at a valuation much lower than large cap pharmaceuticals.
Published:
Last Updated:
October 13, 2016: Here are four stocks trading with relatively heavy volume among 80 equities making new 52-week lows in Thursday’s session. On the NYSE, decliners led advancers by 2 to 1 and on...
Published:
Last Updated: